Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data
This NMA supports the superior efficacy of ARPI combinations against ADT monotherapy, for both OS and PFS. While DAR + ADT demonstrated comparable efficacy to other doublet combinations, it offered a superior safety profile, making it an effective and safe option for managing patients with mCSPC.
Authors
- Keith R. Abrams (ORCID: https://orcid.org/0000-0002-7557-1567)
- Noman Paracha (ORCID: https://orcid.org/0000-0002-3438-4853)
- David Aceituno (ORCID: https://orcid.org/0000-0002-2967-5816)
- Stephen Stefani (ORCID: https://orcid.org/0000-0003-3483-9085)
- Philip Orishaba (ORCID: https://orcid.org/0000-0002-1236-8529)
- Alicia Katherine Morgans (ORCID: https://orcid.org/0000-0002-6563-4587)
- Howard Thom (ORCID: https://orcid.org/0000-0001-8576-5552)
- Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
- Christopher J. D. Wallis (ORCID: https://orcid.org/0000-0002-5990-4026)
- Martin Boegemann
- Quoc-Dien Trinh
- Eva Gallagher
Institutions
- Mount Sinai Hospital (CA)
- University Health Network (CA)
- Pontificia Universidad Católica de Chile (CL)
- German Cancer Research Center (DE)
- University of Toronto (CA)
- University of Bristol (GB)
- University of Warwick (GB)
- Fundação Saúde (BR)
- West Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Bayer (Switzerland) (CH)
- University of Pittsburgh Medical Center (US)
- Carolina Urologic Research Center (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1038/s41391-025-01054-8
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer HealthCare
- National Cancer Institute